Givlaari Effects Sustained Over Time for Patients with Acute Hepatic Porphyria
In 2019, Alnylam Pharmaceuticals received FDA approval for Givlaari, the first RNAi therapy for patients with acute hepatic porphyria. Although some were initially worried about the therapy's safety and…